-
Something wrong with this record ?
The weak association between neurofilament levels at multiple sclerosis onset and cognitive performance after 9 years
L. Friedova, J. Motyl, B. Srpova, J. Oechtering, C. Barro, K. Vodehnalova, M. Andelova, L. Noskova, L. Fialová, EK. Havrdova, D. Horakova, RH. Benedict, J. Kuhle, T. Uher
Language English Country Netherlands
Document type Journal Article
- MeSH
- Biomarkers MeSH
- Intermediate Filaments * MeSH
- Cognition MeSH
- Humans MeSH
- Neurofilament Proteins MeSH
- Cross-Sectional Studies MeSH
- Multiple Sclerosis * MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
BACKGROUND: Neurofilament light chain level in serum (sNfL) and cerebrospinal fluid (CSF-NfL) is a promising biomarker of disease activity in multiple sclerosis (MS). However, predictive value of neurofilaments for development of cognitive decline over long-term follow-up has not been extensively studied. OBJECTIVE: To investigate the relationship between early neurofilament levels and cognitive performance after 9-years. METHODS: We included 58 MS patients from the SET study. sNfL levels were measured at screening, at 1 and 2 years. CSF-NfL were measured in 36 patients at screening. Cognitive performance was assessed by the Brief International Cognitive Assessment for Multiple Sclerosis and the Paced Auditory Serial Addition Test-3 s at baseline, at 1, 2 and 9 years. Association between neurofilament levels and cognition was analyzed using Spearman ́s correlation, logistic regression and mixed models. RESULTS: We did not observe associations among early sNfL levels and cross-sectional or longitudinal cognitive measures, except of a trend for association between higher sNfL levels at screening and lower California Verbal Learning Test-II (CVLT-II) scores at year 1 (rho=-0.31, unadjusted p = 0.028). Higher sNfL level was not associated with increased risk of cognitive decline, except of a trend for greater risk of CVLT-II decrease in patients with higher sNfL levels at 1 year (OR=15.8; 95% CI=1.7-147.0; unadjusted p = 0.015). Similar trends were observed for CSF-NfL. CONCLUSION: We found only weak association between sNfL levels at disease onset and evolution of cognitive performance over long-term follow-up.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21019926
- 003
- CZ-PrNML
- 005
- 20240903114808.0
- 007
- ta
- 008
- 210728e20200928ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.msard.2020.102534 $2 doi
- 035 __
- $a (PubMed)33032055
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Friedová, Lucie, $u Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Katerinska 30, 120 00 Prague, Czech Republic $d 1987- $7 xx0247500
- 245 14
- $a The weak association between neurofilament levels at multiple sclerosis onset and cognitive performance after 9 years / $c L. Friedova, J. Motyl, B. Srpova, J. Oechtering, C. Barro, K. Vodehnalova, M. Andelova, L. Noskova, L. Fialová, EK. Havrdova, D. Horakova, RH. Benedict, J. Kuhle, T. Uher
- 520 9_
- $a BACKGROUND: Neurofilament light chain level in serum (sNfL) and cerebrospinal fluid (CSF-NfL) is a promising biomarker of disease activity in multiple sclerosis (MS). However, predictive value of neurofilaments for development of cognitive decline over long-term follow-up has not been extensively studied. OBJECTIVE: To investigate the relationship between early neurofilament levels and cognitive performance after 9-years. METHODS: We included 58 MS patients from the SET study. sNfL levels were measured at screening, at 1 and 2 years. CSF-NfL were measured in 36 patients at screening. Cognitive performance was assessed by the Brief International Cognitive Assessment for Multiple Sclerosis and the Paced Auditory Serial Addition Test-3 s at baseline, at 1, 2 and 9 years. Association between neurofilament levels and cognition was analyzed using Spearman ́s correlation, logistic regression and mixed models. RESULTS: We did not observe associations among early sNfL levels and cross-sectional or longitudinal cognitive measures, except of a trend for association between higher sNfL levels at screening and lower California Verbal Learning Test-II (CVLT-II) scores at year 1 (rho=-0.31, unadjusted p = 0.028). Higher sNfL level was not associated with increased risk of cognitive decline, except of a trend for greater risk of CVLT-II decrease in patients with higher sNfL levels at 1 year (OR=15.8; 95% CI=1.7-147.0; unadjusted p = 0.015). Similar trends were observed for CSF-NfL. CONCLUSION: We found only weak association between sNfL levels at disease onset and evolution of cognitive performance over long-term follow-up.
- 650 _2
- $a biologické markery $7 D015415
- 650 _2
- $a kognice $7 D003071
- 650 _2
- $a průřezové studie $7 D003430
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a intermediární filamenta $7 D007382
- 650 12
- $a roztroušená skleróza $7 D009103
- 650 _2
- $a neurofilamentové proteiny $7 D016900
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Motyl, Jiri $u Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Katerinska 30, 120 00 Prague, Czech Republic
- 700 1_
- $a Srpová, Barbora $u Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Katerinska 30, 120 00 Prague, Czech Republic $7 xx0321726
- 700 1_
- $a Oechtering, Johanna $u Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, Neurologic Clinic and Policlinic, University Hospital and University of Basel, Switzerland
- 700 1_
- $a Barro, Christian $u Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, Neurologic Clinic and Policlinic, University Hospital and University of Basel, Switzerland
- 700 1_
- $a Vodehnalova, Karolina $u Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Katerinska 30, 120 00 Prague, Czech Republic
- 700 1_
- $a Andelova, Michaela $u Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Katerinska 30, 120 00 Prague, Czech Republic
- 700 1_
- $a Noskova, Libuse $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
- 700 1_
- $a Fialová, Lenka $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
- 700 1_
- $a Havrdova, Eva Kubala $u Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Katerinska 30, 120 00 Prague, Czech Republic
- 700 1_
- $a Horakova, Dana $u Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Katerinska 30, 120 00 Prague, Czech Republic
- 700 1_
- $a Benedict, Ralph Hb $u Department of Neurology, University at Buffalo, Buffalo, NY United States
- 700 1_
- $a Kuhle, Jens $u Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, Neurologic Clinic and Policlinic, University Hospital and University of Basel, Switzerland
- 700 1_
- $a Uher, Tomas $u Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Katerinska 30, 120 00 Prague, Czech Republic. Electronic address: tomas.uher@vfn.cz
- 773 0_
- $w MED00188780 $t Multiple sclerosis and related disorders $x 2211-0356 $g Roč. 46 (20200928), s. 102534
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33032055 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210728 $b ABA008
- 991 __
- $a 20240903114804 $b ABA008
- 999 __
- $a ok $b bmc $g 1690681 $s 1140372
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 46 $c - $d 102534 $e 20200928 $i 2211-0356 $m Multiple sclerosis and related disorders $n Mult Scler Relat Disord $x MED00188780
- LZP __
- $a Pubmed-20210728
